Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.
T cell
food allergy
peptide immunotherapy
phase 1 clinical trial
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
revised:
12
10
2023
received:
12
01
2023
accepted:
06
11
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
Food allergy is a leading cause of anaphylaxis worldwide. Allergen-specific immunotherapy is the only treatment shown to modify the natural history of allergic disease, but application to food allergy has been hindered by risk of severe allergic reactions and short-lived efficacy. Allergen-derived peptides could provide a solution. PVX108 comprises seven short peptides representing immunodominant T-cell epitopes of major peanut allergens for treatment of peanut allergy. Pre-clinical safety of PVX108 was assessed using ex vivo basophil activation tests (n = 185). Clinical safety and tolerability of single and repeat PVX108 doses were evaluated in a first-in-human, randomized, double-blind, placebo-controlled trial in peanut-allergic adults (46 active, 21 placebo). The repeat-dose cohort received six doses over 16 weeks with safety monitored to 21 weeks. Exploratory immunological analyses were performed at pre-dose, Week 21 and Month 18 after treatment. PVX108 induced negligible activation of peanut-sensitised basophils. PVX108 was safe and well tolerated in peanut-allergic adults. There were no treatment-related hypersensitivity events or AEs of clinical concern. The only events occurring more frequently in active than placebo were mild injection site reactions. Exploratory immunological analyses revealed a decrease in the ratio of ST2 This study supports the concept that PVX108 could provide a safe alternative to whole peanut immunotherapies and provides evidence of durable peanut-specific T-cell modulation. Translation of these findings to clinical efficacy in ongoing Phase 2 trials would provide important proof-of-concept for using peptides to treat food allergy.
Sections du résumé
BACKGROUND
BACKGROUND
Food allergy is a leading cause of anaphylaxis worldwide. Allergen-specific immunotherapy is the only treatment shown to modify the natural history of allergic disease, but application to food allergy has been hindered by risk of severe allergic reactions and short-lived efficacy. Allergen-derived peptides could provide a solution. PVX108 comprises seven short peptides representing immunodominant T-cell epitopes of major peanut allergens for treatment of peanut allergy.
METHODS
METHODS
Pre-clinical safety of PVX108 was assessed using ex vivo basophil activation tests (n = 185). Clinical safety and tolerability of single and repeat PVX108 doses were evaluated in a first-in-human, randomized, double-blind, placebo-controlled trial in peanut-allergic adults (46 active, 21 placebo). The repeat-dose cohort received six doses over 16 weeks with safety monitored to 21 weeks. Exploratory immunological analyses were performed at pre-dose, Week 21 and Month 18 after treatment.
RESULTS
RESULTS
PVX108 induced negligible activation of peanut-sensitised basophils. PVX108 was safe and well tolerated in peanut-allergic adults. There were no treatment-related hypersensitivity events or AEs of clinical concern. The only events occurring more frequently in active than placebo were mild injection site reactions. Exploratory immunological analyses revealed a decrease in the ratio of ST2
CONCLUSION
CONCLUSIONS
This study supports the concept that PVX108 could provide a safe alternative to whole peanut immunotherapies and provides evidence of durable peanut-specific T-cell modulation. Translation of these findings to clinical efficacy in ongoing Phase 2 trials would provide important proof-of-concept for using peptides to treat food allergy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : U19 AI125378-01
Pays : United States
Informations de copyright
© 2023 Aravax Pty Ltd. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Lieberman JA, Gupta RS, Knibb RC, et al. The global burden of illness of peanut allergy: a comprehensive literature review. Allergy. 2021;76:1367-1384.
Alvaro-Lozano M, Akdis CA, Akdis M, et al. EAACI allergen immunotherapy user's guide. Pediatr Allergy Immunol. 2020;31(Suppl 25):1-101.
Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019;393:2222-2232.
Sampath V, Abrams EM, Adlou B, et al. Food allergy across the globe. J Allergy Clin Immunol. 2021;148:1347-1364.
Vazquez-Ortiz M, Turner PJ. Improving the safety of oral immunotherapy for food allergy. Pediatr Allergy Immunol. 2016;27:117-125.
Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135:1275-1282.e1-6.
Fleischer DM, Burks AW, Vickery BP, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol. 2013;131:119-127.e1-7.
Kim EH, Yang L, Ye P, et al. Long-term sublingual immunotherapy for peanut allergy in children: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2019;144:1320-1326.e1.
Sampson HA, Shreffler WG, Yang WH, et al. Effect of varying doses of Epicutaneous immunotherapy vs placebo on reaction to Peanut protein exposure among patients with Peanut sensitivity: a randomized clinical trial. JAMA. 2017;318:1798-1809.
Fleischer DM, Greenhawt M, Sussman G, et al. Effect of Epicutaneous immunotherapy vs placebo on reaction to Peanut protein ingestion among children with Peanut allergy: the PEPITES randomized clinical trial. JAMA. 2019;321:946-955.
Fleischer DM, Shreffler WG, Campbell DE, et al. Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results. J Allergy Clin Immunol. 2020;146:863-874.
Vickery BP, Scurlock AM, Kulis M, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133:468-475.
Sampath V, Nadeau KC. Newly identified T cell subsets in mechanistic studies of food immunotherapy. J Clin Investig. 2019;129:1431-1440.
Zhang H, Kong H, Zeng X, Guo L, Sun X, He S. Subsets of regulatory T cells and their roles in allergy. J Transl Med. 2014;12:125.
Bernaldo de Quiros E, Seoane-Reula E, Alonso-Lebrero E, Pion M, Correa-Rocha R. The role of regulatory T cells in the acquisition of tolerance to food allergens in children. Allergol Immunopathol (Madr). 2018;46:612-618.
Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med. 1983;157:1434-1447.
Schwartz RH. T cell anergy. Annu Rev Immunol. 2003;21:305-334.
Prickett SR, Rolland JM, O'Hehir RE. Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy. Clin Exp Allergy. 2015;45:1015-1026.
Moldaver DM, Bharhani MS, Rudulier CD, Wattie J, Inman MD, Larché M. Induction of bystander tolerance and immune deviation after Fel d 1 peptide immunotherapy. J Allergy Clin Immunol. 2019;143:1087-1099.e4.
Campbell JD, Buckland KF, McMillan SJ, et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med. 2009;206:1535-1547.
Gri G, Piconese S, Frossi B, et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity. 2008;29:771-781.
Dwyer DF, Ordovas-Montanes J, Allon SJ, et al. Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation. Sci Immunol. 2021;6:eabb7221.
Couroux P, Patel D, Armstrong K, Larché M, Hafner RP. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy. 2015;45:974-981.
Ellis AK, Frankish CW, Armstrong K, et al. Persistence of the clinical effect of grass allergen peptide immunotherapy after the second and third grass pollen seasons. J Allergy Clin Immunol. 2020;145:610-618.e9.
Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131:103-109.e7.
Larché M. Mechanisms of peptide immunotherapy in allergic airways disease. Ann Am Thorac Soc. 2014;11:S292-S296.
Müller U, Akdis CA, Fricker M, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998;101:747-754.
Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy. 2008;63:1455-1463.
Shamji MH, Ljørring C, Francis JN, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy: functional IgG4 correlates with clinical efficacy of allergen specific immunotherapy. Allergy. 2012;67:217-226.
Prickett SR, Voskamp AL, Dacumos-Hill A, Symons K, Rolland JM, O'Hehir RE. Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol. 2011;127:608-615.e5.
Prickett SR, Voskamp AL, Phan T, et al. Ara h 1 CD4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic. Clin Exp Allergy. 2013;43:684-697.
Varshney P, Jones SM, Scurlock AM, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127:654-660.
Bajzik V, DeBerg HA, Garabatos N, et al. Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses. Allergy. 2022;77:2534-2548.
Kwok WW, Roti M, DeLong JH, et al. Direct ex vivo analysis of allergen-specific CD4+ T cells. J Allergy Clin Immunol. 2010;125:1407-1409.e1.
Wambre E, Bajzik V, DeLong JH, et al. A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders. Sci Transl Med. 2017;9:eaam9171.
Calise J, Garabatos N, Bajzik V, et al. Optimal human pathogenic TH2 cell effector function requires local epithelial cytokine signaling. J Allergy Clin Immunol. 2021;148:867-875.e4.
Xu T, Stewart KM, Wang X, et al. Metabolic control of TH17 and induced Treg cell balance by an epigenetic mechanism. Nature. 2017;548:228-233.
Castro G, Liu X, Ngo K, et al. RORγt and RORα signature genes in human Th17 cells. PLoS ONE. 2017;12:e0181868.
Kono M, Yoshida N, Maeda K, et al. Pyruvate dehydrogenase phosphatase catalytic subunit 2 limits Th17 differentiation. Proc Natl Acad Sci USA. 2018;115:9288-9293.
Di Giorgio E, Wang L, Xiong Y, et al. MEF2D sustains activation of effector Foxp3+ Tregs during transplant survival and anticancer immunity. J Clin Investig. 2020;130:6242-6260.
Shi H, Chapman NM, Wen J, et al. Amino acids license kinase mTORC1 activity and Treg cell function via small G proteins rag and Rheb. Immunity. 2019;51:1012-1027.e7.
Bettinger P, Roman C. The induction of FoxP3 in naive T cells is dependent upon the transcription factors TFE3 and TFEB. (163.4). J Immunol. 2012;188:163.4.
Oppenheimer J, Nelson H, Bock S, Christensen F, Leung D. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90:256-262.
Nelson H, Lahr J, Rule R, Bock A, Leung D. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract1. J Allergy Clin Immunol. 1997;99:744-751.
Wood RA, Sicherer SH, Burks AW, et al. A phase 1 study of heat/phenol-killed, E. Coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy. 2013;68:803-808.
Bindslev-Jensen C, de Kam P-J, van Twuijver E, et al. SCIT-treatment with a chemically modified, aluminum hydroxide adsorbed Peanut extract (HAL-MPE1) was generally safe and well tolerated and showed immunological changes in Peanut allergic patients. J Allergy Clin Immunol. 2017;139:AB191.
Bird JA, Spergel JM, Jones SM, et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract. 2018;6:476-485.e3.
The PALISADE Group of Clinical Investigators. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379:1991-2001.
Jones SM, Agbotounou WK, Fleischer DM, et al. Safety of epicutaneous immunotherapy for the treatment of peanut allergy: a phase 1 study using the Viaskin patch. J Allergy Clin Immunol. 2016;137:1258-1261.e10.
Jones SM, Sicherer SH, Burks AW, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139:1242-1252.e9.
Pongracic JA, Gagnon R, Sussman G, et al. Safety of Epicutaneous immunotherapy in Peanut-allergic children: REALISE randomized clinical trial results. J Allergy Clin Immunol Pract. 2022;10:1864-1873.e10.
Epstein-Rigbi N, Levy MB, Nachshon L, et al. Efficacy and safety of food allergy oral immunotherapy in adults. Allergy. 2023;78:803-811.
Kleij HPM, Warmenhoven HJM, Ree R, et al. Chemically modified peanut extract shows increased safety while maintaining immunogenicity. Allergy. 2019;74:986-995.
Tscheppe A, Palmberger D, van Rijt L, et al. Development of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity. J Allergy Clin Immunol. 2020;145:229-238.
King N, Helm R, Stanley JS, et al. Allergenic characteristics of a modified peanut allergen. Mol Nutr Food Res. 2005;49:963-971.
Castenmiller C, Stigler M, Kirpas ME, et al. Plant-based enveloped Ara h 2 bioparticles display exceptional hypo-allergenicity. Clin Exp Allergy. 2023;53:577-581.
Calise J, DeBerg H, Garabatos N, et al. Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy. J Allergy Clin Immunol. 2023;152:155-166.e9.
Du R, Zhao H, Yan F, Li H. IL-17+ Foxp3+ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells. J Leukoc Biol. 2014;96:39-48.
Ziegler SF, Buckner JH. FOXP3 and the regulation of Treg/Th17 differentiation. Microbes Infect. 2009;11:594-598.
Dioszeghy V, Mondoulet L, Puteaux E, et al. Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut. Cell Mol Immunol. 2017;14:770-782.
Tordesillas L, Mondoulet L, Blazquez AB, Benhamou P-H, Sampson HA, Berin MC. Epicutaneous immunotherapy induces gastrointestinal LAP + regulatory T cells and prevents food-induced anaphylaxis. J Allergy Clin Immunol. 2017;139:189-201.e4.
Berin MC, Agashe C, Burks AW, et al. Allergen-specific T cells and clinical features of food allergy: lessons from CoFAR immunotherapy cohorts. J Allergy Clin Immunol. 2021;149(4):1373-1382.e12.
Liu G, Liu M, Wang J, Mou Y, Che H. The role of regulatory T cells in Epicutaneous immunotherapy for food allergy. Front Immunol. 2021;12:660974.
Schoos A-MM, Bullens D, Chawes BL, et al. Immunological outcomes of allergen-specific immunotherapy in food allergy. Front Immunol. 2020;11:568598.
Wambre E, DeLong JH, James EA, et al. Specific immunotherapy modifies allergen-specific CD4+ T-cell responses in an epitope-dependent manner. J Allergy Clin Immunol. 2014;133:872-879.e7.
Ryan JF, Hovde R, Glanville J, et al. Successful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets. Proc Natl Acad Sci USA. 2016;113:E1286-E1295.
Monian B, Tu AA, Ruiter B, et al. Peanut oral immunotherapy differentially suppresses clonally distinct subsets of T helper cells. J Clin Investig. 2022;132:e150634.
Hafner R, Salapatek A, Larché M, Ahenkorah B, Patel P, Pawsey S. Initial evidence of sustained efficacy of house dust mite synthetic peptide Immuno regulatory epitopes 2 years after a short course of treatment in house dust mite (HDM) allergic subjects. J Allergy Clin Immunol. 2015;135:AB142.
Simms E, Syed I, Rudulier C, Larché M. Peptide immunotherapy; short but Long lasting? Curr Treat Options Allergy. 2015;2:64-71.
Jones SM, Burks AW, Keet C, et al. Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. J Allergy Clin Immunol. 2016;137:1117-1127.e10.